The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Comparison of MAFLD and NAFLD diagnostic criteria in real world
Abstract
Background and aims: Metabolic associated fatty liver disease (MAFLD) is a novel concept proposed in 2020, the utility of which has not been tested and validated in real world. We aimed to compare the characteristics of MAFLD and non‐alcoholic fatty liver disease (NAFLD). Methods: The data was retrieved from the third National Health and Nutrition Examination Surveys of the United States, which is an unbiased survey dataset and frequently used for the study of fatty liver disease. Results: A total of 13 083 cases with completed ultrasonography and laboratory data were identified from the NHANES III database. MAFLD was diagnosed in 4087/13 083 (31.24%) participants, while NAFLD in 4347/13 083 (33.23%) amongst the overall population and 4347/12 045 (36.09%) in patients without alcohol intake and other liver diseases. Compared with NAFLD, MAFLD patients were significantly older, had higher BMI level, higher proportions of metabolic comorbidities (diabetes, hypertension) and higher HOMA‐IR, lipid and liver enzymes. MAFLD patients with alcohol consumption were younger than those without, and more likely to be male. They had less metabolic disorder but higher liver enzymes. There were more cases with advance fibrosis in MAFLD patients with alcohol consumption. Conclusion: MAFLD definition is more practical for identifying patients with fatty liver disease with high risk of disease progression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Younossi, Z. M., Koenig, A. B., Abdelatif, D., Fazel, Y., Henry, L., & Wymer, M. (2016) · Hepatology · doi:10.1002/hep.28431 · Cited by 10,781
Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention
Younossi, Z., Anstee, Q. M., Marietti, M., Hardy, T., Henry, L., Eslam, M., George, J., & Bugianesi, E. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.109 · Cited by 5,249
Sterling, R. K., Lissen, E., Clumeck, N., Sola, R., Correa, M. C., Montaner, J., S. Sulkowski, M., Torriani, F. J., Dieterich, D. T., Thomas, D. L., et al. (2006) · Hepatology · doi:10.1002/hep.21178 · Cited by 5,021
EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease
(2016) · Journal of Hepatology · doi:10.1016/j.jhep.2015.11.004 · Cited by 4,836
Eslam, M., Newsome, P. N., Sarin, S. K., Anstee, Q. M., Targher, G., Romero-Gomez, M., Zelber-Sagi, S., Wai-Sun Wong, V., Dufour, J.-F., Schattenberg, J. M., et al. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.03.039 · Cited by 4,472
MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease
Eslam, M., Sanyal, A. J., George, J., Sanyal, A., Neuschwander-Tetri, B., Tiribelli, C., Kleiner, D. E., Brunt, E., Bugianesi, E., Yki-Järvinen, H., et al. (2020) · Gastroenterology · doi:10.1053/j.gastro.2019.11.312 · Cited by 3,286
Angulo, P., Hui, J. M., Marchesini, G., Bugianesi, E., George, J., Farrell, G. C., Enders, F., Saksena, S., Burt, A. D., Bida, J. P., et al. (2007) · Hepatology · doi:10.1002/hep.21496 · Cited by 3,203
Noninvasive assessment of liver disease in patients with nonalcoholic fatty liver disease
Castera, L., Friedrich-Rust, M., & Loomba, R. (2019) · Gastroenterology · doi:10.1053/j.gastro.2018.12.036 · Cited by 1,494
Cause, Pathogenesis, and Treatment of Nonalcoholic Steatohepatitis
Diehl, A. M., & Day, C. (2017) · New England Journal of Medicine · doi:10.1056/nejmra1503519 · Cited by 1,283
A position statement on NAFLD/NASH based on the EASL 2009 special conference
Ratziu, V., Bellentani, S., Cortez-Pinto, H., Day, C., & Marchesini, G. (2010) · Journal of Hepatology · doi:10.1016/j.jhep.2010.04.008 · Cited by 1,058
Cited by
Eslam, M., Sarin, S. K., Wong, V. W.-S., Fan, J.-G., Kawaguchi, T., Ahn, S. H., Zheng, M.-H., Shiha, G., Yilmaz, Y., Gani, R., et al. (2020) · Hepatology International · doi:10.1007/s12072-020-10094-2 · Cited by 833
Targher, G., Tilg, H., & Byrne, C. D. (2021) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(21)00020-0 · Cited by 586
MAFLD: How is it different from NAFLD?
Gofton, C., Upendran, Y., Zheng, M.-H., & George, J. (2023) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2022.0367 · Cited by 423
MAFLD identifies patients with significant hepatic fibrosis better than NAFLD
Yamamura, S., Eslam, M., Kawaguchi, T., Tsutsumi, T., Nakano, D., Yoshinaga, S., Takahashi, H., Anzai, K., George, J., & Torimura, T. (2020) · Liver International · doi:10.1111/liv.14675 · Cited by 401
Sun, D.-Q., Jin, Y., Wang, T.-Y., Zheng, K. I., Rios, R. S., Zhang, H.-Y., Targher, G., Byrne, C. D., Yuan, W.-J., & Zheng, M.-H. (2021) · Metabolism · doi:10.1016/j.metabol.2020.154433 · Cited by 308
Metadata
- Authors
- Lin, S., Huang, J., Wang, M., Kumar, R., Liu, Y., Liu, S., Wu, Y., Wang, X., & Zhu, Y.
- Venue
- Liver International
- Publisher
- Wiley
- Published
- 2020-07-26
- Volume
- 40
- Issue
- 9
- Pages
- 2082-2089
- ISSN
- 0106-9543 (ISSN-L)
- 1478-3223
- 1478-3231
- OpenAlex
- W3032413621
- Cited by
- 516
- References
- 22
- FWCI
- 57.14
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Comparison of MAFLD and NAFLD diagnostic criteria in real world. https://app.cochat.ai/papers/10.1111/liv.14548
- The paper
- Lin, S., Huang, J., Wang, M., Kumar, R., Liu, Y., Liu, S., Wu, Y., Wang, X., & Zhu, Y. (2020). Comparison of MAFLD and NAFLD diagnostic criteria in real world. Liver International. https://doi.org/10.1111/liv.14548
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.